News


2020

May 12, 2020

A Landmark Lumella Preeclampsia point-of-care test study published in British Journal of Obstetrics & Gynecology.

A large, independent and prospective study in a low-resource setting demonstrated Lumella Preeclampsia rapid point-of-care test clinical utility for diagnosis of preeclampsia.

Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study

February 20, 2020

Publication of Lumella Preeclampsia test for short-term prediction of preeclampsia.

The study shows Lumella PE test has the best performance for short-term prediction of preeclampsia in 1-4 weeks.
Huhn et al. BMC Pregnancy and Childbirth (2020) 20:128

Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study


2019

February 7, 2019

Diabetomics launches Lumella point-of-care test in India

biospectrumindia.com


2018

October 2018

Regulatory approvals

Lumella point-of care test for rapid assessment of Preeclampsia product is CE marked.

Lumella_news_10-2019

June 22, 2018

Diabetomics exhibits at ADA annual meeting

ADA_2018

March 3, 2018

Diabetomics inauguration of its manufacturing facility in India.
thisweekindia.news

Manufacturing_3

2017

June 15, 2017

Diabetes Tech at ADA’s 77th Scientific Sessions
healthline.com


June 12, 2017

New Point-of-Care C Peptide Test Shows Promise
endocrinologyadvisor.com


June 10, 2017

Diabetomics exhibits at ADA annual meeting

2017ADANews

2016

June 11, 2016

Diabetomics exhibits at ADA annual meeting

ada_meeting2

February 22, 2016

World’s first non-invasive test for diabetes coming up in Medak, Hyderabad
ETHealthWorld.com


2014

September 9, 2014

Hillsboro company unveils new test to detect common prenatal problem in early stages
Portland Business Journal


September 9, 2014

Early Preeclampsia Detection Test Under Development
MPR


September 9, 2014

DiabetOmics Unveils New Test for the Early Detection, Assessment, and Monitoring of Preeclampsia
Press Release


July 30, 2014

Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia
American Journal of Obstetrics & Gynecology


2013

September, 2013

Diabetomics paper on first trimester detection of gestational diabetes published in ACOG journal
Obstetrics & Gynecology


September, 2013

Diabetomics receives patent on non-invasive salivary diagnostics for prediabetes and diabetes
US Patent


September, 2013

Gestational diabetes early detection press
Clinical Advisor


July 14, 2013

Diabetomics conducts a national symposium on Autoimmune Diabetes Diagnosis and Interventions
Autoimmune Diabetes Symposium


July, 2013

Diabetomics receives three patents on non-invasive salivary diagnostics for prediabetes and diabetes
US Patent


June, 2013

Diabetomics presents at ADA annual meeting
ADA presentation


2012

July 28, 2012

Now, a Non-invasive Test for Diabetes
Today’s Paper


June 8-12, 2012

First-trimester Maternal Serum Biomarkers for Prediction of Gestational Diabetes
ADA Scientific Sessions


June 8-12, 2012

Diabetes Autoantibody Analysis in Human Saliva
ADA Scientific Sessions


June 8-12, 2012

Non-invasive Salivary Protein Glycosylation as a Short Term Glycemic Index
ADA Scientific Sessions


May 1, 2012

Methods for Detecting Prediabetes and Diabetes Using Differential Protein Glycosylation
US Patent

Scroll to top

Choose site:

Diabetomics India (diabetomics.in)

Diabetomics, Inc. USA (diabetomics.com)

In response to COVID-19 pandemic, Diabetomics is leveraging its oral fluid rapid test technology to develop a home use SARS-CoV-2 antibody test.

covabscreen.com
X myStickymenu